

Table 5 Incidence of retinal NV and associated risk factors[†]

Characteristic	Number at Risk	Incident NV Cases	Incidence Rate (% per eye-year)	Crude hazard ratio (HR) (95% CI)	Adjusted HR (95% CI)
Number of eyes	8487	88	0.33		
Age<35	3342	48	0.44	1.77 (1.1- 2.8)*	2.4 (1.5 - 3.9)**
Female (compared to male)	5399	52	0.31	0.81 (0.51 - 1.3)	0.75 (0.47 - 1.2)
Behçet disease	226	5	0.42	1.5 (0.6 - 3.8)	0.63 (0.26 – 1.5)
Systemic lupus erythematosus	78	5	1.2	4.6 (1.6 - 14)**	3.5 (1.1 – 11)*
Sarcoidosis	647	8	0.30	0.99 (0.41 - 2.4)	0.94 (0.39 - 2.3)
HLA-B27+	1100	6	0.17	0.47 (0.21 - 1.1)	1.3 (0.55 - 3.1)
HLA-A29+	179	2	0.26	0.84 (0.21 – 3.4)	0.44 (0.10 – 1.9)
Polyarteritis nodosa	12	1	1.5	5.5 (0.73 – 41)	7.2 (1.2 – 44)*
Granulomatosis with polyangiitis	4	0	0	0 (0 – 100) ^{††}	0 (0 – 99) ^{††}
Other arteritis	8	0	0	0 (0 – 64) ^{††}	0 (0 – 60) ^{††}
Scleroderma	6	0	0	0 (0 – 63) ^{††}	0 (0 – 360) ^{††}
Sjögren’s syndrome	16	0	0	0 (0 – 11) ^{††}	0 (0 – 8.4) ^{††}
Spondyloarthropathy (any)	482	3	0.16	0.53 (0.17 – 1.6)	1.2 (0.35 – 3.8)
Polymyositis	3	0	0	0 (0 – 45) ^{††}	0 (0 – 47) ^{††}
Rheumatoid arthritis	166	0	0	0 (0 – 2.0) ^{††}	0 (0 – 2.1)
Juvenile idiopathic arthritis	451	3	0.17	0.52 (0.16 – 1.6)	0.91 (0.26 – 3.2)
Relapsing polychondritis	8	0	0	0 (0 – 49) ^{††}	0 (0 – 250) ^{††}
Cogan’s syndrome	2	0	0	0 (0 – 110) ^{††}	0 (0 – 210) ^{††}
Crohn’s disease	116	0	0	0 (0 – 2.4) ^{††}	0 (0 – 5.3) ^{††}
Ulcerative Colitis	106	1	0.24	0.82 (0.11 – 5.9)	1.2 (0.14 – 11)
Multiple Sclerosis	147	1	0.14	0.50 (0.070 – 3.5)	0.44 (0.060 – 3.2)
Familial systemic granulomatosis	0	0	0	--	--

Characteristic	Number at Risk	Incident NV Cases	Incidence Rate (% per eye-year)	Crude hazard ratio (HR) (95% CI)	Adjusted HR (95% CI)
Hypertension	1791	30	0.40	1.5 (0.93 - 2.5)	1.5 (0.89 - 2.4)
Diabetes	550	12	0.61	2.1 (0.98 - 4.3)	2.3 (1.1 - 4.9)*
Bilateral	5590	80	0.39	3.3 (1.6 - 6.8)**	2.0 (0.95 - 4.2)
Current Smoker (vs. never smoker)	1545	24	0.52	2.3 (1.3 - 4.1)**	1.9 (1.1 - 3.4)*
Former Smoker (vs. never smoker)	889	12	0.39	1.8 (0.84 - 3.8)	1.7 (0.79 - 3.7)
Uveitis diagnosis ≤ 1 years (vs >5 years)	4387	49	0.39	2.6 (1.3 - 5.4)**	2.4 (1.1 - 5.0)*
Uveitis diagnosis between 1 and 5 years (vs >5 years)	2238	30	0.40	2.8 (1.3 - 6.0)**	2.6 (1.2 - 6.0)*
Site of uveitis					
Anterior	4857	15	0.11	1.0 (reference group)	1.0 (reference group)
Intermediate	1358	20	0.44	4.0 (2.0 - 8.4)**	3.1 (1.5 - 6.6)**
Posterior	1242	30	0.68	6.7 (3.3 - 14)**	5.2 (2.5 - 11)**
Panuveitis	1030	23	0.60	5.8 (2.8 - 12)**	4.3 (2.0 - 9.3)**
Activity					
Inactive	--	40	0.22	1.00 (reference group)	1.0 (reference group)
Slightly active	--	18	0.80	2.8 (1.5 - 5.0)**	2.4 (1.3 - 4.4)**
Active	--	29	0.86	2.7 (1.6 - 4.5)**	2.1 (1.2 - 3.7)**
Anterior Chamber Cell					
No Cell	--	53	0.30	1.00 (reference group)	1.00 (reference group)
0.5+	--	15	0.48	1.4 (0.74 - 2.6)	1.5 (0.81 - 2.8)
1+	--	7	0.43	1.2 (0.54 - 2.7)	1.4 (0.60 - 3.1)
2+	--	8	0.99	2.4 (1.1 - 5.6)*	2.7 (1.2 - 6.0)*
3+	--	4	1.3	3.2 (1.2 - 8.8)*	3.9 (1.3 - 11)*

Characteristic	Number at Risk	Incident NV Cases	Incidence Rate (% per eye-year)	Crude hazard ratio (HR) (95% CI)	Adjusted HR (95% CI)
Vitreous Cell					
No Cell	--	49	0.28	1.00 (reference group)	1.00 (reference group)
0.5+	--	10	0.43	1.3 (0.63 - 2.8)	0.95 (0.45 - 2.0)
1+	--	16	0.78	2.3 (1.3 - 4.2)**	1.7 (0.94 - 3.1)
2+	--	7	0.66	1.7 (0.70 - 4.1)	1.2 (0.48 - 3.0)
3+	--	1	0.39	0.96 (0.14 - 6.8)	0.65 (0.090 - 4.6)
Vitreous Haze					
None	--	59	0.29	1.00 (reference group)	1.00 (reference group)
1+	--	18	1.0	3.2 (1.3 - 5.9)*	2.3(1.1 - 5.0)*
2+	--	2	0.45	1.2 (0.11 - 4.7)*	0.97(0.10 - 4.1)*
3+	--	0	0	0.00(0.00 - 7.25)*	0.00(0.00 - 6.08)*
Macular edema	--	14	0.72	2.0 (1.1 - 3.8)*	1.5 (0.75 - 3.1)
Epiretinal membrane	--	6	0.32	1.2 (0.51 - 2.7)	0.83 (0.37 - 1.9)
Exudative retinal detachment	--	3	2.5	6.3 (2.1 - 19)**	4.1 (1.3 - 13)*
Choroidal neovascularization	--	2	3.0	6.7 (0.90 - 49)	4.1 (0.46 - 36)
Snowballs present	--	7	1.2	2.9 (1.4 - 6.3)**	2.3 (1.0 - 5.4)
Retinal vascular sheathing	--	14	1.8	5.2 (2.7 - 10)**	2.6 (1.4 - 4.9)**
Retinal vascular occlusion	--	4	9.0	20 (7.3 - 57)**	10 (3.0 - 33)**
Active inflammatory chorioretinal lesions	--	1	0.17	0.35 (0.05 - 2.6)	0.16 (0.020 - 1.2)

† Adjusted analysis adjusts for age category, gender, bilateral inflammation, smoking status, hypertension, diabetes, primary ocular location of inflammation, systemic lupus erythematosus, and time from diagnosis. For associated characteristics which could vary from visit to visit (such as activity), the analysis was done using a time varying approach. For these characteristics, no value for number of eyes is given for variables analyzed as time-dependent covariates.

^{††}For characteristics which were not present in any patients with retinal NV, a hazard ratio (HR) of zero is given but an estimated confidence interval is calculated using a profile likelihood method (see text for details).

These conditions with low numbers of retinal neovascularization are available in supplemental tables online and omitted from the print versions for brevity. Data reporting risk based on gradings of anterior chamber cell, vitreous cell, and vitreous haze are available in the supplemental table.

Takayasu arteritis and dermatomyositis had fewer than 5 observations in both the prevalence and incidence analyses and are omitted from the tables. Although there were 8 eyes with familial systemic granulomatosis in the prevalence analysis, none were eligible for the incidence analysis.

*= $p < 0.05$

**= $p < 0.01$